Skip to content

Regeneron Pharmaceuticals

NASDAQ: REGN · USD

Regeneron Pharmaceuticals financials

6 charts

Revenue

USD millions

$4,290.7M
Regeneron Pharmaceuticals Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2010 Q2$115.886M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$105.979M; −8.5% vs FY 2010 Q2
FY 2010 Q4$133.675M; +26.1% vs FY 2010 Q3
FY 2011 Q1$112.204M; −16.1% vs FY 2010 Q4
FY 2011 Q2$107.81M; −3.9% vs FY 2011 Q1
FY 2011 Q3$102.833M; −4.6% vs FY 2011 Q2
FY 2011 Q4$122.977M; +19.6% vs FY 2011 Q3
FY 2012 Q1$231.789M; +88.5% vs FY 2011 Q4
FY 2012 Q2$304.399M; +31.3% vs FY 2012 Q1
FY 2012 Q3$427.687M; +40.5% vs FY 2012 Q2
FY 2012 Q4$414.602M; −3.1% vs FY 2012 Q3
FY 2013 Q1$439.664M; +6.0% vs FY 2012 Q4
FY 2013 Q2$457.642M; +4.1% vs FY 2013 Q1
FY 2013 Q3$597.027M; +30.5% vs FY 2013 Q2
FY 2013 Q4$610.412M; +2.2% vs FY 2013 Q3
FY 2014 Q1$625.74M; +2.5% vs FY 2013 Q4
FY 2014 Q2$665.7M; +6.4% vs FY 2014 Q1
FY 2014 Q3$725.788M; +9.0% vs FY 2014 Q2
FY 2014 Q4$802.329M; +10.5% vs FY 2014 Q3
FY 2015 Q1$869.612M; +8.4% vs FY 2014 Q4
FY 2015 Q2$998.617M; +14.8% vs FY 2015 Q1
FY 2015 Q3$1,137.422M; +13.9% vs FY 2015 Q2
FY 2015 Q4$1,098.077M; −3.5% vs FY 2015 Q3
FY 2016 Q1$1,200.849M; +9.4% vs FY 2015 Q4
FY 2016 Q2$1,212.629M; +1.0% vs FY 2016 Q1
FY 2016 Q3$1,220.122M; +0.6% vs FY 2016 Q2
FY 2016 Q4$1,226.827M; +0.5% vs FY 2016 Q3
FY 2017 Q1$1,318.991M; +7.5% vs FY 2016 Q4
FY 2017 Q2$1,470.116M; +11.5% vs FY 2017 Q1
FY 2017 Q3$1,500.673M; +2.1% vs FY 2017 Q2
FY 2017 Q4$1,582.447M; +5.4% vs FY 2017 Q3
FY 2018 Q1$1,511.485M; −4.5% vs FY 2017 Q4
FY 2018 Q2$1,608.022M; +6.4% vs FY 2018 Q1
FY 2018 Q3$1,663.496M; +3.4% vs FY 2018 Q2
FY 2018 Q4$1,927.8M; +15.9% vs FY 2018 Q3
FY 2019 Q1$1,711.8M; −11.2% vs FY 2018 Q4
FY 2019 Q2$1,933.7M; +13.0% vs FY 2019 Q1
FY 2019 Q3$2,048.4M; +5.9% vs FY 2019 Q2
FY 2019 Q4$2,169.5M; +5.9% vs FY 2019 Q3
FY 2020 Q1$1,828.2M; −15.7% vs FY 2019 Q4
FY 2020 Q2$1,952M; +6.8% vs FY 2020 Q1
FY 2020 Q3$2,294M; +17.5% vs FY 2020 Q2
FY 2020 Q4$2,422.9M; +5.6% vs FY 2020 Q3
FY 2021 Q1$2,528.7M; +4.4% vs FY 2020 Q4
FY 2021 Q2$5,138.5M; +103.2% vs FY 2021 Q1
FY 2021 Q3$3,452.8M; −32.8% vs FY 2021 Q2
FY 2021 Q4$4,951.7M; +43.4% vs FY 2021 Q3
FY 2022 Q1$2,965.1M; −40.1% vs FY 2021 Q4
FY 2022 Q2$2,857.2M; −3.6% vs FY 2022 Q1
FY 2022 Q3$2,936.2M; +2.8% vs FY 2022 Q2
FY 2022 Q4$3,414.4M; +16.3% vs FY 2022 Q3
FY 2023 Q1$3,162.1M; −7.4% vs FY 2022 Q4
FY 2023 Q2$3,158.1M; −0.1% vs FY 2023 Q1
FY 2023 Q3$3,362.7M; +6.5% vs FY 2023 Q2
FY 2023 Q4$3,434.3M; +2.1% vs FY 2023 Q3
FY 2024 Q1$3,145M; −8.4% vs FY 2023 Q4
FY 2024 Q2$3,547.1M; +12.8% vs FY 2024 Q1
FY 2024 Q3$3,720.7M; +4.9% vs FY 2024 Q2
FY 2024 Q4$3,789.2M; +1.8% vs FY 2024 Q3
FY 2025 Q1$3,028.7M; −20.1% vs FY 2024 Q4
FY 2025 Q2$3,675.6M; +21.4% vs FY 2025 Q1
FY 2025 Q3$3,754.3M; +2.1% vs FY 2025 Q2
FY 2025 Q4$3,884.3M; +3.5% vs FY 2025 Q3
FY 2026 Q1$3,605.4M; −7.2% vs FY 2025 Q4
FY 2026 Q2$4,290.7M; +19.0% vs FY 2026 Q1
Jun 30, 2010 through Sep 25, 2026

Free cash flow

USD millions

$572.8M
Regeneron Pharmaceuticals Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2010 Q2$-35.629M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$138.566M; +488.9% vs FY 2010 Q2
FY 2010 Q4$-73.961M; −153.4% vs FY 2010 Q3
FY 2011 Q1$-32.746M; +55.7% vs FY 2010 Q4
FY 2011 Q2$-48.914M; −49.4% vs FY 2011 Q1
FY 2011 Q3$-55.633M; −13.7% vs FY 2011 Q2
FY 2011 Q4$-61.606M; −10.7% vs FY 2011 Q3
FY 2012 Q1$-98.096M; −59.2% vs FY 2011 Q4
FY 2012 Q2$-91.249M; +7.0% vs FY 2012 Q1
FY 2012 Q3$-12.63M; +86.2% vs FY 2012 Q2
FY 2012 Q4$78.023M; +717.8% vs FY 2012 Q3
FY 2013 Q1$65.045M; −16.6% vs FY 2012 Q4
FY 2013 Q2$93.711M; +44.1% vs FY 2013 Q1
FY 2013 Q3$60.764M; −35.2% vs FY 2013 Q2
FY 2013 Q4$207.805M; +242.0% vs FY 2013 Q3
FY 2014 Q1$-11.295M; −105.4% vs FY 2013 Q4
FY 2014 Q2$256.917M; +2374.6% vs FY 2014 Q1
FY 2014 Q3$83.788M; −67.4% vs FY 2014 Q2
FY 2014 Q4$80.741M; −3.6% vs FY 2014 Q3
FY 2015 Q1$-201.664M; −349.8% vs FY 2014 Q4
FY 2015 Q2$3.713M; +101.8% vs FY 2015 Q1
FY 2015 Q3$746.754M; +20011.9% vs FY 2015 Q2
FY 2015 Q4$104.044M; −86.1% vs FY 2015 Q3
FY 2016 Q1$-74.754M; −171.8% vs FY 2015 Q4
FY 2016 Q2$276.312M; +469.6% vs FY 2016 Q1
FY 2016 Q3$532.473M; +92.7% vs FY 2016 Q2
FY 2016 Q4$227.424M; −57.3% vs FY 2016 Q3
FY 2017 Q1$305.44M; +34.3% vs FY 2016 Q4
FY 2017 Q2$-85.419M; −128.0% vs FY 2017 Q1
FY 2017 Q3$355.179M; +515.8% vs FY 2017 Q2
FY 2017 Q4$459.286M; +29.3% vs FY 2017 Q3
FY 2018 Q1$539.368M; +17.4% vs FY 2017 Q4
FY 2018 Q2$282.548M; −47.6% vs FY 2018 Q1
FY 2018 Q3$346.715M; +22.7% vs FY 2018 Q2
FY 2018 Q4$643.369M; +85.6% vs FY 2018 Q3
FY 2019 Q1$822.7M; +27.9% vs FY 2018 Q4
FY 2019 Q2$93.7M; −88.6% vs FY 2019 Q1
FY 2019 Q3$435.6M; +364.9% vs FY 2019 Q2
FY 2019 Q4$648.4M; +48.9% vs FY 2019 Q3
FY 2020 Q1$527.9M; −18.6% vs FY 2019 Q4
FY 2020 Q2$813.5M; +54.1% vs FY 2020 Q1
FY 2020 Q3$-407.5M; −150.1% vs FY 2020 Q2
FY 2020 Q4$1,069.6M; +362.5% vs FY 2020 Q3
FY 2021 Q1$553.2M; −48.3% vs FY 2020 Q4
FY 2021 Q2$478.2M; −13.6% vs FY 2021 Q1
FY 2021 Q3$3,280.4M; +586.0% vs FY 2021 Q2
FY 2021 Q4$2,217.6M; −32.4% vs FY 2021 Q3
FY 2022 Q1$1,959.9M; −11.6% vs FY 2021 Q4
FY 2022 Q2$410.8M; −79.0% vs FY 2022 Q1
FY 2022 Q3$486.4M; +18.4% vs FY 2022 Q2
FY 2022 Q4$1,567.7M; +222.3% vs FY 2022 Q3
FY 2023 Q1$1,189.4M; −24.1% vs FY 2022 Q4
FY 2023 Q2$909.4M; −23.5% vs FY 2023 Q1
FY 2023 Q3$938.3M; +3.2% vs FY 2023 Q2
FY 2023 Q4$838.3M; −10.7% vs FY 2023 Q3
FY 2024 Q1$1,378.6M; +64.5% vs FY 2023 Q4
FY 2024 Q2$173.5M; −87.4% vs FY 2024 Q1
FY 2024 Q3$1,049.3M; +504.8% vs FY 2024 Q2
FY 2024 Q4$1,063.2M; +1.3% vs FY 2024 Q3
FY 2025 Q1$815.8M; −23.3% vs FY 2024 Q4
FY 2025 Q2$925.4M; +13.4% vs FY 2025 Q1
FY 2025 Q3$1,417.3M; +53.2% vs FY 2025 Q2
FY 2025 Q4$922M; −34.9% vs FY 2025 Q3
FY 2026 Q1$848.3M; −8.0% vs FY 2025 Q4
FY 2026 Q2$572.8M; −32.5% vs FY 2026 Q1

Net margin

%

30.23%
Regeneron Pharmaceuticals Net margin. Reported fiscal history.
Fiscal period%
FY 2010 Q2-21.98%
FY 2010 Q3-31.96%
FY 2010 Q4-10.92%
FY 2011 Q1-38.72%
FY 2011 Q2-57.98%
FY 2011 Q3-60.65%
FY 2011 Q4-43.46%
FY 2012 Q15.03%
FY 2012 Q225.21%
FY 2012 Q344.77%
FY 2012 Q4113.46%
FY 2013 Q122.49%
FY 2013 Q219.09%
FY 2013 Q323.67%
FY 2013 Q415.86%
FY 2014 Q110.46%
FY 2014 Q213.93%
FY 2014 Q310.98%
FY 2014 Q413.73%
FY 2015 Q18.74%
FY 2015 Q219.49%
FY 2015 Q318.5%
FY 2015 Q414.12%
FY 2016 Q113.8%
FY 2016 Q216.18%
FY 2016 Q321.7%
FY 2016 Q420.63%
FY 2017 Q118.87%
FY 2017 Q226.38%
FY 2017 Q325.88%
FY 2017 Q410.97%
FY 2018 Q131.62%
FY 2018 Q234.29%
FY 2018 Q335.75%
FY 2018 Q442.56%
FY 2019 Q126.94%
FY 2019 Q29.99%
FY 2019 Q332.69%
FY 2019 Q436.51%
FY 2020 Q134.16%
FY 2020 Q245.97%
FY 2020 Q336.71%
FY 2020 Q447.43%
FY 2021 Q144.1%
FY 2021 Q260.31%
FY 2021 Q347.27%
FY 2021 Q445.01%
FY 2022 Q132.83%
FY 2022 Q229.82%
FY 2022 Q344.81%
FY 2022 Q435.06%
FY 2023 Q125.86%
FY 2023 Q230.66%
FY 2023 Q329.97%
FY 2023 Q433.77%
FY 2024 Q122.96%
FY 2024 Q240.38%
FY 2024 Q336.03%
FY 2024 Q424.22%
FY 2025 Q126.7%
FY 2025 Q237.86%
FY 2025 Q338.89%
FY 2025 Q421.74%
FY 2026 Q120.17%
FY 2026 Q230.23%

P/E

× · TTM · Daily

19.3×
Regeneron Pharmaceuticals P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-04-30—2012-03-31
2012-05-31—2012-03-31
2012-06-29—2012-03-31
2012-07-31—2012-06-30
2012-08-31—2012-06-30
2012-09-28—2012-06-30
2012-10-3172.8×2012-09-30
2012-11-3090.32×2012-09-30
2012-12-3187.51×2012-09-30
2013-01-3188.98×2012-09-30
2013-02-2829.4×2012-12-31
2013-03-2831.05×2012-12-31
2013-04-3037.87×2012-12-31
2013-05-3131.59×2013-03-31
2013-06-2829.37×2013-03-31
2013-07-3135.27×2013-03-31
2013-08-3031.73×2013-06-30
2013-09-3040.97×2013-06-30
2013-10-3137.66×2013-06-30
2013-11-2942.98×2013-09-30
2013-12-3140.26×2013-09-30
2014-01-3142.21×2013-09-30
2014-02-2877.28×2013-12-31
2014-03-3169.8×2013-12-31
2014-04-3069.01×2013-12-31
2014-05-3088.06×2014-03-31
2014-06-3081.04×2014-03-31
2014-07-3190.72×2014-03-31
2014-08-2999.96×2014-06-30
2014-09-30102.83×2014-06-30
2014-10-31112.3×2014-06-30
2014-11-28145.98×2014-09-30
2014-12-31143.93×2014-09-30
2015-01-30146.18×2014-09-30
2015-02-27145.19×2014-09-30
2015-03-31158.39×2014-09-30
2015-04-30160.49×2014-09-30
2015-05-29172.87×2014-12-31
2015-06-30172.05×2014-12-31
2015-07-31186.73×2014-12-31
2015-08-31173.18×2014-12-31
2015-09-30156.87×2014-12-31
2015-10-30187.98×2014-12-31
2015-11-30106.78×2015-09-30
2015-12-31106.46×2015-09-30
2016-01-2982.38×2015-09-30
2016-02-2975.31×2015-09-30
2016-03-3170.68×2015-09-30
2016-04-2973.87×2015-09-30
2016-05-3178.23×2015-09-30
2016-06-3068.49×2015-09-30
2016-07-2983.37×2015-09-30
2016-08-3176.98×2015-09-30
2016-09-3078.84×2015-09-30
2016-10-3167.66×2015-09-30
2016-11-3074.37×2015-09-30
2016-12-3071.99×2015-09-30
2017-01-3170.46×2015-09-30
2017-02-2873.24×2015-09-30
2017-03-3175.99×2015-09-30
2017-04-2876.18×2015-09-30
2017-05-3190.02×2015-09-30
2017-06-3096.31×2015-09-30
2017-07-3196.41×2015-09-30
2017-08-3197.44×2015-09-30
2017-09-2987.68×2015-09-30
2017-10-3178.96×2015-09-30
2017-11-3070.96×2015-09-30
2017-12-2973.73×2015-09-30
2018-01-3171.9×2015-09-30
2018-02-2829.34×2017-09-30
2018-03-2931.53×2017-09-30
2018-04-3027.81×2017-09-30
2018-05-3127.5×2017-09-30
2018-06-2931.59×2017-09-30
2018-07-3133.7×2017-09-30
2018-08-3137.24×2017-09-30
2018-09-2837×2017-09-30
2018-10-3131.06×2017-09-30
2018-11-3033.48×2017-09-30
2018-12-3134.2×2017-09-30
2019-01-3139.31×2017-09-30
2019-02-2839.44×2017-09-30
2019-03-2937.6×2017-09-30
2019-04-3031.42×2017-09-30
2019-05-3127.63×2017-09-30
2019-06-2828.66×2017-09-30
2019-07-3127.9×2017-09-30
2019-08-3026.56×2017-09-30
2019-09-3025.4×2017-09-30
2019-10-3128.04×2017-09-30
2019-11-2933.79×2017-09-30
2019-12-3134.38×2017-09-30
2020-01-3130.94×2017-09-30
2020-02-2828.46×2018-09-30
2020-03-3131.26×2018-09-30
2020-04-3033.67×2018-09-30
2020-05-2930.95×2020-03-31
2020-06-3031.49×2020-03-31
2020-07-3131.92×2020-03-31
2020-08-3124.5×2020-06-30
2020-09-3022.12×2020-06-30
2020-10-3021.48×2020-06-30
2020-11-3018.62×2020-09-30
2020-12-3117.44×2020-09-30
2021-01-2918.18×2020-09-30
2021-02-2614.38×2020-12-31
2021-03-3115.1×2020-12-31
2021-04-3015.36×2020-12-31
2021-05-2813.87×2021-03-31
2021-06-3015.42×2021-03-31
2021-07-3015.86×2021-03-31
2021-08-3112.02×2021-06-30
2021-09-3010.81×2021-06-30
2021-10-2911.43×2021-06-30
2021-11-3011.37×2021-06-30
2021-12-3111.28×2021-06-30
2022-01-3110.87×2021-06-30
2022-02-2811.04×2021-06-30
2022-03-3112.47×2021-06-30
2022-04-2911.77×2021-06-30
2022-05-3111.87×2021-06-30
2022-06-3010.55×2021-06-30
2022-07-2910.39×2021-06-30
2022-08-3110.38×2021-06-30
2022-09-3012.3×2021-06-30
2022-10-3113.37×2021-06-30
2022-11-3012.24×2021-09-30
2022-12-3011.75×2021-09-30
2023-01-3112.35×2021-09-30
2023-02-2812.38×2021-09-30
2023-03-3113.38×2021-09-30
2023-04-2813.05×2021-09-30
2023-05-3111.98×2021-09-30
2023-06-3011.7×2021-09-30
2023-07-3112.08×2021-09-30
2023-08-3113.46×2021-09-30
2023-09-2913.4×2021-09-30
2023-10-3112.7×2021-09-30
2023-11-3013.41×2021-09-30
2023-12-2914.3×2021-09-30
2024-01-3115.35×2021-09-30
2024-02-2927.78×2023-12-31
2024-03-2827.68×2023-12-31
2024-04-3025.61×2023-12-31
2024-05-3129.24×2024-03-31
2024-06-2831.36×2024-03-31
2024-07-3132.2×2024-03-31
2024-08-3031.63×2024-06-30
2024-09-3028.07×2024-06-30
2024-10-3122.38×2024-06-30
2024-11-2918.73×2024-09-30
2024-12-3117.78×2024-09-30
2025-01-3116.8×2024-09-30
2025-02-2817.99×2024-12-31
2025-03-3116.33×2024-12-31
2025-04-3014.8×2025-03-31
2025-05-3012.12×2025-03-31
2025-06-3012.98×2025-03-31
2025-07-3113.48×2025-03-31
2025-08-2914.14×2025-06-30
2025-09-3013.7×2025-06-30
2025-10-3115.26×2025-09-30
2025-11-2818.27×2025-09-30
2025-12-3118.07×2025-09-30
2026-01-3017.36×2025-09-30
2026-02-2718.69×2025-12-31
2026-03-3118.47×2025-12-31
2026-04-3017.22×2026-03-31
2026-05-2914.97×2026-03-31
2026-06-3015.18×2026-03-31
2026-07-3118.68×2026-06-30
2026-08-3119.57×2026-06-30
2026-09-2519.3×2026-06-30
Mean 47.05×Median 30.21×36% below median

ROIC

% · Annual / TTM

—
Reported borrowing balances are unavailable in the extracted statements for this period.
Regeneron Pharmaceuticals ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$1,506.4M
Regeneron Pharmaceuticals capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q2100% · $22.581MUnavailableUnavailableUnavailableUnavailable100% · $22.581M
FY 2010 Q3100% · $22.103MUnavailableUnavailableUnavailableUnavailable100% · $22.103M
FY 2010 Q4100% · $32.262MUnavailableUnavailableUnavailableUnavailable100% · $32.262M
FY 2011 Q1100% · $22.166MUnavailableUnavailableUnavailableUnavailable100% · $22.166M
FY 2011 Q2100% · $14.864MUnavailableUnavailableUnavailableUnavailable100% · $14.864M
FY 2011 Q3100% · $8.898MUnavailableUnavailableUnavailableUnavailable100% · $8.898M
FY 2011 Q4100% · $11.289MUnavailableUnavailableUnavailableUnavailable100% · $11.289M
FY 2012 Q1100% · $11.055MUnavailableUnavailableUnavailableUnavailable100% · $11.055M
FY 2012 Q2100% · $12.872MUnavailableUnavailableUnavailableUnavailable100% · $12.872M
FY 2012 Q3100% · $10.248MUnavailableUnavailableUnavailableUnavailable100% · $10.248M
FY 2012 Q4100% · $15.162MUnavailableUnavailableUnavailableUnavailable100% · $15.162M
FY 2013 Q1100% · $21.203MUnavailableUnavailableUnavailableUnavailable100% · $21.203M
FY 2013 Q2100% · $34.453MUnavailableUnavailableUnavailableUnavailable100% · $34.453M
FY 2013 Q3100% · $31.691MUnavailableUnavailableUnavailable0% · $0M100% · $31.691M
FY 2013 Q4100% · $68.976MUnavailableUnavailableUnavailable0% · $0M100% · $68.976M
FY 2014 Q1100% · $64.822MUnavailableUnavailableUnavailable0% · $0M100% · $64.822M
FY 2014 Q253.69% · $70.873MUnavailableUnavailableUnavailable46.31% · $61.125M100% · $131.998M
FY 2014 Q3100% · $79.769MUnavailableUnavailableUnavailable0% · $0M100% · $79.769M
FY 2014 Q442.43% · $117.542MUnavailableUnavailableUnavailable57.57% · $159.514M100% · $277.056M
FY 2015 Q187.25% · $114.162MUnavailableUnavailableUnavailable12.75% · $16.686M100% · $130.848M
FY 2015 Q265.33% · $239.893MUnavailableUnavailableUnavailable34.67% · $127.315M100% · $367.208M
FY 2015 Q398.65% · $146.099MUnavailableUnavailableUnavailable1.35% · $2.006M100% · $148.105M
FY 2015 Q489.68% · $177.779MUnavailableUnavailableUnavailable10.32% · $20.46M100% · $198.239M
FY 2016 Q199.43% · $104.094MUnavailableUnavailableUnavailable0.57% · $0.598M100% · $104.692M
FY 2016 Q292.71% · $138.836MUnavailableUnavailableUnavailable7.29% · $10.911M100% · $149.747M
FY 2016 Q3100% · $118.556MUnavailableUnavailableUnavailable0% · $0M100% · $118.556M
FY 2016 Q499.84% · $150.455MUnavailableUnavailableUnavailable0.16% · $0.244M100% · $150.699M
FY 2017 Q179.69% · $50.461MUnavailableUnavailableUnavailable20.31% · $12.861M100% · $63.322M
FY 2017 Q2100% · $54.849MUnavailableUnavailableUnavailable0% · $0M100% · $54.849M
FY 2017 Q3100% · $59.653MUnavailableUnavailableUnavailable0% · $0M100% · $59.653M
FY 2017 Q4100% · $107.663MUnavailable0% · $0MUnavailable0% · $0M100% · $107.663M
FY 2018 Q1100% · $79.375MUnavailable0% · $0MUnavailableUnavailable100% · $79.375M
FY 2018 Q2100% · $112.017MUnavailable0% · $0MUnavailableUnavailable100% · $112.017M
FY 2018 Q396.04% · $106.246MUnavailable3.96% · $4.378MUnavailableUnavailable100% · $110.624M
FY 2018 Q499.97% · $85.462MUnavailable0.03% · $0.022MUnavailableUnavailable100% · $85.484M
FY 2019 Q188.14% · $74.3MUnavailable11.86% · $10MUnavailableUnavailable100% · $84.3M
FY 2019 Q2100% · $94.6MUnavailable0% · $0MUnavailableUnavailable100% · $94.6M
FY 2019 Q386.25% · $121.7MUnavailable13.75% · $19.4MUnavailableUnavailable100% · $141.1M
FY 2019 Q436.06% · $139MUnavailable63.94% · $246.5MUnavailableUnavailable100% · $385.5M
FY 2020 Q134.66% · $170.1MUnavailable65.34% · $320.7MUnavailableUnavailable100% · $490.8M
FY 2020 Q22.51% · $129.9MUnavailable97.49% · $5,052.9MUnavailableUnavailable100% · $5,182.8M
FY 2020 Q362.45% · $153.2MUnavailable37.55% · $92.1MUnavailableUnavailable100% · $245.3M
FY 2020 Q429.75% · $161.4MUnavailable70.25% · $381.1MUnavailableUnavailable100% · $542.5M
FY 2021 Q127.31% · $115.3MUnavailable72.69% · $306.9MUnavailableUnavailable100% · $422.2M
FY 2021 Q232.73% · $148.5MUnavailable67.27% · $305.2MUnavailableUnavailable100% · $453.7M
FY 2021 Q344.46% · $133.2M0% · $0M55.54% · $166.4MUnavailableUnavailable100% · $299.6M
FY 2021 Q415.16% · $154.9M0% · $0M84.84% · $866.9MUnavailableUnavailable100% · $1,021.8M
FY 2022 Q128.37% · $141.8MUnavailable71.63% · $358.1MUnavailableUnavailable100% · $499.9M
FY 2022 Q229.96% · $153.6MUnavailable70.04% · $359MUnavailableUnavailable100% · $512.6M
FY 2022 Q313.23% · $142.5M0% · $0M86.77% · $934.6MUnavailableUnavailable100% · $1,077.1M
FY 2022 Q426.09% · $152.2M0% · $0M73.91% · $431.1MUnavailableUnavailable100% · $583.3M
FY 2023 Q120.05% · $178.2MUnavailable79.95% · $710.7MUnavailableUnavailable100% · $888.9M
FY 2023 Q214.09% · $113MUnavailable85.91% · $688.8MUnavailableUnavailable100% · $801.8M
FY 2023 Q322.75% · $176M6.61% · $51.1M70.64% · $546.5MUnavailableUnavailable100% · $773.6M
FY 2023 Q446.2% · $251.4M0.7% · $3.8M53.11% · $289MUnavailableUnavailable100% · $544.2M
FY 2024 Q131.49% · $133.9MUnavailable68.51% · $291.3M0% · $0MUnavailable100% · $425.2M
FY 2024 Q223.01% · $180.5MUnavailable76.99% · $603.9M0% · $0MUnavailable100% · $784.4M
FY 2024 Q324.76% · $241.9M0% · $0M75.24% · $735.1M0% · $0MUnavailable100% · $977M
FY 2024 Q416.86% · $199.6M0.97% · $11.5M82.17% · $973M0% · $0MUnavailable100% · $1,184.1M
FY 2025 Q116.8% · $229.3MUnavailable76.32% · $1,041.4M6.87% · $93.8MUnavailable100% · $1,364.5M
FY 2025 Q215.95% · $219MUnavailable77.31% · $1,061.5M6.74% · $92.6MUnavailable100% · $1,373.1M
FY 2025 Q320.99% · $201.4M0.31% · $3M69.2% · $664M9.5% · $91.2MUnavailable100% · $959.6M
FY 2025 Q424.54% · $248.7M0.03% · $0.3M66.28% · $671.7M9.15% · $92.7MUnavailable100% · $1,013.4M
FY 2026 Q120.54% · $230.6MUnavailable70.75% · $794.3M8.71% · $97.8MUnavailable100% · $1,122.7M
FY 2026 Q215.95% · $240.2MUnavailable77.63% · $1,169.4M6.43% · $96.8MUnavailable100% · $1,506.4M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Regeneron Pharmaceuticals.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources